Bristol Myers Squibb Reports Q1 Results, Reaffirms Guidance, and Highlights Key Pipeline Progress
BMY sits 36% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb announced Q1 2026 financial results with revenue growth and reaffirmed full-year guidance, alongside several positive pipeline and regulatory milestones.
Key Events · Earnings and Guidance · BMY
-
Q1 2026 Financial Performance
Revenues increased 3% to $11.5 billion, and GAAP EPS rose 9% to $1.31. Non-GAAP EPS decreased 12% to $1.58.
-
Full-Year Guidance Reaffirmed
The company reaffirmed its 2026 financial guidance, with total revenues and non-GAAP EPS trending towards the upper end of the previously provided ranges.
-
Strong Growth Portfolio Performance
Growth Portfolio revenues increased 12% (+9% Ex-FX) to $6.2 billion, driven by products like Camzyos, Breyanzi, and Reblozyl.
-
Key Pipeline & Regulatory Milestones
Achieved multiple clinical and regulatory milestones, including FDA approval for Sotyktu in psoriatic arthritis, positive Phase 3 data for mezigdomide in multiple myeloma, and FDA approval for Opdivo in classical Hodgkin Lymphoma.
Analysis · BMY · Life Sciences
Bristol Myers Squibb reported a 3% increase in first-quarter revenues to $11.5 billion and a 9% rise in GAAP EPS to $1.31. While non-GAAP EPS saw a 12% decline, the company reaffirmed its full-year 2026 financial guidance, with revenues and non-GAAP EPS trending towards the upper end of the ranges. This indicates management's confidence in future performance, driven by strong growth in its newer portfolio and significant advancements in its pipeline, including multiple regulatory approvals and positive clinical trial readouts. Investors should monitor the continued performance of the growth portfolio and the progression of key pipeline assets.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMY was trading at $57.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $117.6B. The 52-week trading range was $42.52 to $62.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.